Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Prostatic Neoplasms 2Smoking Cessation 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Cardiotoxicity 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 50Cyclophosphamide 50Mycophenolic Acid 36Cyclosporine 33Busulfan 33Whole-Body Irradiation 32Peripheral Blood Stem Cell Transplantation 31Antilymphocyte Serum 24fludarabine 21Cord Blood Stem Cell Transplantation 21Tacrolimus 20Cytarabine 19Filgrastim 18Melphalan 17Radiotherapy 15Methylprednisolone 13Methotrexate 13Thiotepa 10Granulocyte Colony-Stimulating Factor 10Etoposide 9Cyclosporins 7Azacitidine 7thymoglobulin 5sargramostim 5Idarubicin 5Clofarabine 5Arsenic Trioxide 5Transplantation 4Sirolimus 4Gemtuzumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Anemia, Refractory, with Excess of Blasts × sulforaphane × Clear all
NCT07297576 2025-12-30

Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation

Institute of Hematology & Blood Diseases Hospital, China

Phase NA Recruiting
36 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡